{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T13:30:40Z","timestamp":1747834240745,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.eprac.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T08:56:19Z","timestamp":1704444979000},"page":"327-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-1021","authenticated-orcid":false,"given":"Kathryn","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Tough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Belikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Colville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eprac.2024.01.003_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.01.003_bib2","first-page":"1139","article-title":"Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period","volume":"112","author":"Hay","year":"1992","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.003_bib3","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1210\/jc.2008-1931","article-title":"Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment","volume":"94","author":"Bonnet","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.eprac.2024.01.003_bib4","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","article-title":"Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer","volume":"366","author":"Mallick","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2024.01.003_bib5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","article-title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer","volume":"366","author":"Schlumberger","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.003_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hed.26594","article-title":"Low- and high-dose radioiodine ablation for low-\/intermediate-risk differentiated thyroid cancer in China: large randomized clinical trial","volume":"43","author":"Dong","year":"2021","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.003_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2213-8587(18)30306-1","article-title":"Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial","volume":"7","author":"Dehbi","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2024.01.003_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(18)30113-X","article-title":"Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial","volume":"6","author":"Schlumberger","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2024.01.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12515","article-title":"Guidelines for the management of thyroid cancer","volume":"81","author":"Perros","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.eprac.2024.01.003_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.003_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.003_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1524-4733.2009.00650.x","article-title":"Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective","volume":"13","author":"Mernagh","year":"2010","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.eprac.2024.01.003_bib14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2024.01.003_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa2111953","article-title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer","volume":"386","author":"Leboulleux","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"S2","key":"10.1016\/j.eprac.2024.01.003_bib16","first-page":"S1145","article-title":"Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid patients?","volume":"34","author":"Hackshaw","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2024.01.003_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1507\/endocrj.EJ20-0063","article-title":"BRAF and TERT promoter mutations: clinical application in thyroid cancer","volume":"67","author":"Chung","year":"2020","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.003_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12149-019-01432-y","article-title":"Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer","volume":"34","author":"Abe","year":"2020","journal-title":"Ann Nucl Med"},{"issue":"6","key":"10.1016\/j.eprac.2024.01.003_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MNM.0000000000000296","article-title":"Low-dose radioiodine ablation in\u00a0differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin","volume":"36","author":"Zhang","year":"2015","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.eprac.2024.01.003_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/cen.12301","article-title":"Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer","volume":"80","author":"Tsirona","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.003_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3803\/EnM.2020.747","article-title":"Clinical outcomes after early and delayed radioiodine remnant ablation in patients with low-risk papillary thyroid carcinoma: propensity score matching analysis","volume":"35","author":"Ahn","year":"2020","journal-title":"Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.003_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/cen.13551","article-title":"Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer","volume":"88","author":"Li","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.003_bib23","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1210\/clinem\/dgab691","article-title":"Low-iodine diet of 4 days is sufficient preparation for 131I therapy in differentiated thyroid cancer patients","volume":"107","author":"Dekker","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.003_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/jc.2006-1345","article-title":"131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review","volume":"92","author":"Hackshaw","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.01.003_bib25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/thy.2013.0157","article-title":"High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal","volume":"24","author":"Bartenstein","year":"2014","journal-title":"Thyroid"},{"issue":"26","key":"10.1016\/j.eprac.2024.01.003_bib26","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1200\/JCO.2015.61.6722","article-title":"Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial","volume":"33","author":"Borget","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2024.01.003_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1210\/jc.2005-2064","article-title":"A\u00a0comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal","volume":"91","author":"Schroeder","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.003_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/thy.2009.0187","article-title":"Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma","volume":"20","author":"Lee","year":"2010","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2024.01.003_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2013.07.003","article-title":"Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer","volume":"27","author":"Spencer","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:16:22Z","timestamp":1712034982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1530891X24000156"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.01.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}